QuellTX
Catherine Williamson is an experienced patent attorney currently working at Quell Therapeutics since November 2021. Previously, Catherine held the position of Senior Associate, UK & European Patent Attorney at Haseltine Lake Kempner from May 2019 to November 2021, and at Haseltine Lake LLP from February 2011 to April 2019, where Catherine also started as a Trainee Patent Attorney. Catherine Williamson holds a Master’s Degree (MSc) in Molecular Medicine from Imperial College London and a Bachelor’s Degree (BSc) in Natural Sciences (Biology and Chemistry) from Durham University. Education was completed at Watford Grammar School for Girls.
This person is not in the org chart
This person is not in any teams
QuellTX
4 followers
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions.Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cellengineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.